Brii Biosciences Management

Management criteria checks 3/4

Brii Biosciences' CEO is Zhi Hong, appointed in Jan 2018, has a tenure of 6.25 years. total yearly compensation is CN¥14.31M, comprised of 47.5% salary and 52.5% bonuses, including company stock and options. directly owns 4.46% of the company’s shares, worth HK$29.92M. The average tenure of the management team and the board of directors is 2.3 years and 3.7 years respectively.

Key information

Zhi Hong

Chief executive officer

CN¥14.3m

Total compensation

CEO salary percentage	47.5%
CEO tenure	6.3yrs
CEO ownership	4.5%
Management average tenure	2.3yrs
Board average tenure	3.7yrs

Recent management updates

Recent updates

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Nov 19

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Jul 26

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

Jan 12

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Mar 24

CEO Compensation Analysis

How has Zhi Hong's remuneration changed compared to Brii Biosciences's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-CN¥175m
Sep 30 2023	n/a	n/a	-CN¥251m
Jun 30 2023	n/a	n/a	-CN¥327m
Mar 31 2023	n/a	n/a	-CN¥405m
Dec 31 2022	CN¥14m	CN¥7m	-CN¥484m
Sep 30 2022	n/a	n/a	-CN¥1b
Jun 30 2022	n/a	n/a	-CN¥2b
Mar 31 2022	n/a	n/a	-CN¥3b
Dec 31 2021	CN¥65m	CN¥37m	-CN¥4b
Sep 30 2021	n/a	n/a	-CN¥4b
Jun 30 2021	n/a	n/a	-CN¥4b
Mar 31 2021	n/a	n/a	-CN¥3b
Dec 31 2020	CN¥22m	CN¥5m	-CN¥1b
Dec 31 2019	CN¥20m	CN¥4m	-CN¥521m

Compensation vs Market: Zhi's total compensation ($USD1.98M) is above average for companies of similar size in the Hong Kong market ($USD233.25K).

Compensation vs Earnings: Zhi's compensation has been consistent with company performance over the past year.

CEO

Zhi Hong (59 yo)

6.3yrs

Tenure

CN¥14,305,000

Compensation

Dr. Zhi Hong, PhD, co-founded Brii Biosciences Limited in 2018 and serves as its Executive Chairman of the Board, Chief Executive Officer & Executive Director since 2018. Prior to starting Brii Bio, Dr. Ho...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Zhi Hong	Co-founder	6.3yrs	CN¥14.31m	4.46% CN¥ 29.9m
Ankang Li	Chief Financial & Strategy Officer	3yrs	CN¥11.32m	0.17% CN¥ 1.1m
Eleanor de Groot	Chief Technology Officer	1.7yrs	no data	no data
Brian Johns	Chief Scientific Officer	less than a year	no data	no data
Sarah Qiu	Associate Director of Investor Relations	no data	no data	no data
Karen Del Barrio Neuendorff	Chief People Officer & Head of Human Resources	2.3yrs	no data	no data
Coy Stout	Head of Patient Advocacy	2.6yrs	no data	no data
Lianhong Xu	Head of Discovery	no data	no data	no data
Qing Zhu	Head of China Research & Development	3.8yrs	no data	no data
David Margolis	Chief Medical Officer	no data	no data	no data
Susannah Cantrell	Chief Business Officer	1.8yrs	no data	no data
Aleksandar Skuban	Head of Central Nervous System Diseases Therapy Area Head	1.7yrs	no data	no data

2.3yrs

Average Tenure

54yo

Average Age

Experienced Management: 2137's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Zhi Hong	Co-founder	6.3yrs	CN¥14.31m	4.46% CN¥ 29.9m
Ankang Li	Chief Financial & Strategy Officer	1.6yrs	CN¥11.32m	0.17% CN¥ 1.1m
Robert Taylor Nelsen	Non-Executive Director	5.8yrs	no data	no data
Yiu Wa Tsui	Independent Non-executive Director	no data	CN¥922.00k	0.010% CN¥ 67.1k
Gregg Alton	Independent Non-executive Director	no data	CN¥922.00k	0.010% CN¥ 67.1k
Taiyin Yang	Independent Non-Executive Director	1.6yrs	CN¥308.00k	0.015% CN¥ 100.3k
Martin J. Murphy	Independent Non-executive Director	no data	CN¥922.00k	0.010% CN¥ 67.1k
Hui Tang	Independent Non-executive Director	no data	CN¥922.00k	0.010% CN¥ 67.1k

3.7yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 2137's board of directors are considered experienced (3.7 years average tenure).

Brii Biosciences Management

Management criteria checks 3/4

Key information

Recent management updates

Brii Biosciences Limited, Annual General Meeting, Jun 25, 2024

Brii Biosciences Limited Announces Executive Changes

High number of new directors

Brii Biosciences Limited Announces Executive Changes

Brii Biosciences Limited Announces Board and Committee Changes

Brii Biosciences Limited Announces Board Changes

Recent updates

Brii Biosciences Limited, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Brii Biosciences Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023

New minor risk - Share price stability

Consensus EPS estimates upgraded to CN¥0.92 loss

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B

Consensus revenue estimates increase by 2,527%

First half 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.48 loss in 1H 2022)

Brii Biosciences Limited to Report First Half, 2023 Results on Aug 22, 2023

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Brii Biosciences Limited Announces Executive Changes

Shionogi Inc. entered into a definitive agreement to acquire Qpex Biopharma, Inc. from Brii Biosciences Limited (SEHK:2137) and Others for $140 million.

Brii Biosciences Limited Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating BRII-297

Consensus revenue estimates fall by 100%

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Brii Biosciences Limited Announces Interim Findings from A Phase 2 Study

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

No longer forecast to breakeven

Brii Biosciences Limited Provides Update on Strategic Clinical Development Progress

High number of new directors

Brii Biosciences Announces New Data from Two Phase 1 Studies

Brii Biosciences Limited Announces Topline Results from a Phase 1 Study Evaluating its Long-Acting, Single-Injection Therapy, BRII-296, in the Development for the Treatment of Postpartum Depression

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Brii Biosciences Limited Announces Executive Changes

Brii Biosciences Limited Announces Board and Committee Changes

Brii Biosciences Limited Announces Board Changes

Consensus forecasts updated

No longer forecast to breakeven

Brii Biosciences Limited Appoints Eleanor De Groot as Senior Vice President and Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Brii Biosciences Limited Appoints Eleanor De Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Brii Biosciences Limited to Report First Half, 2022 Results on Aug 23, 2022

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer

Consensus revenue estimates increase by 14%

Brii Biosciences Limited Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Forecast to breakeven in 2023

Brii Bio Announces Positive Data Demonstrating Its Long-Acting Covid-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron Ba.2 Subvariant

No longer forecast to breakeven

Insufficient new directors

Brii Biosciences Limited Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022

Brii Biosciences Limited, Annual General Meeting, Jun 22, 2022

Brii Biosciences Limited, Annual General Meeting, Jun 22, 2022

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Brii Biosciences Limited to Report Fiscal Year 2021 Results on Mar 22, 2022

Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources

Brii Biosciences Limited Doses First Patient in Phase 2a/2b Clinical Trial of BrII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

Brii Biosciences Limited Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

Brii Biosciences Announces Completion of Enrollment in the Phase 3 National Institutes of Health ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19

Brii Biosciences Limited has completed an IPO in the amount of HKD 2.482655 billion.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age